Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic cancer.

ABSTRACT:

Background

Nanoliposomal irinotecan combined with fluorouracil plus leucovorin (nal-IRI + 5-FU/LV) is a standard second-line treatment for patients with advanced pancreatic cancer. Despite its efficacy, the prognostic factors for treatment efficacy remain unclear in clinical practice.

Objectives

To investigate prognostic factors for survival with nal-IRI + 5-FU/LV.

Design

Single-centre retrospective cohort.

Methods

We included 204 patients who were treated with nal-IRI + 5-FU/LV at our institution between July 2020 and March 2022. These patients had unresectable or recurrent pancreatic adenocarcinoma refractory to a gemcitabine-containing regimen. A Cox regression hazard model was used to explore prognostic factors for overall survival (OS).

Results

Of t

SUBMITTER: Kobayashi S 

PROVIDER: S-EPMC12202952 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature